导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.20% | 4099/4773 |
| 近一周 | -4.70% | 5061/5462 |
| 近一月 | -4.73% | 2685/5421 |
| 近一季 | 0.93% | 610/5209 |
| 近半年 | -12.98% | 3814/4920 |
| 近一年 | -19.09% | 3900/4366 |
| 近两年 | 12.65% | 2783/2954 |
| 近三年 | -9.23% | 2022/2253 |
| 成立以来 | -7.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.06% 4017/4961 |
-14.63% 4587/5312 |
- - |
- - |
| 2025 | 6.83% 2942/4813 |
-0.09% 2054/3635 |
5.10% 650/4076 |
4.94% 3633/4524 |
-3.05% 3245/4813 |
| 2024 | 2.84% 1954/3463 |
-4.64% 1727/2808 |
-8.27% 2201/3014 |
18.21% 1041/3129 |
-0.55% 1459/3463 |
| 2023 | -9.03% 1092/2656 |
3.28% 1225/2280 |
-5.94% 1564/2385 |
-3.74% 979/2515 |
-2.72% 517/2655 |
| 2022 | -18.60% 731/2207 |
-17.13% 1181/1919 |
6.12% 768/2016 |
-15.60% 1318/2113 |
9.67% 202/2208 |
| 2021 | -8.89% 1061/1822 |
-1.44% 491/1255 |
4.56% 871/1330 |
-15.20% 1382/1466 |
4.25% 346/1822 |
| 2020 | 27.41% 580/1250 |
-1.70% 230/1028 |
19.27% 303/1067 |
8.61% 704/1164 |
0.06% 1063/1184 |
| 2019 | 22.94% 639/1092 |
24.40% 511/754 |
-8.72% 604/804 |
1.71% 367/850 |
6.45% 609/918 |
| 2018 | -24.56% 326/834 |
- - |
- - |
- - |
-10.45% 196/691 |
| 2017 | 12.37% 282/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.06% 349/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发养老指数A VS. 长安沪深300非周期A(740101) |